The SARS-CoV-2 crisis and the prophylactic vaccines developed in response to it brought mRNA therapeutics to the cutting edge of medicine. Consumer acceptance has risen, and mRNA vaccination studies for people with cancer have surged. The result: the global market for mRNA therapeutics, now estimated at nearly $55 billion, is expected to reach $128 billion by the end of the decade.

Developers are eager to explore this new frontier, but they face a big challenge: sourcing raw materials Many things can go wrong, from contaminants to inconsistent quality. In this playbook, we explore:

• The role raw materials play in supporting consistency in process development
• The importance of quality control—and the downstream ramifications of choosing suboptimal materials
• How drug developers can evaluate materials and suppliers to find solutions that meet their needs

​